Skip to content
Shield Bio logo

Shield Bio

Shield Bio is a YC Summer 2016 (S16) company. Based in San Jose, CA, USA. Team of 28.

  • Healthcare
  • Genomics
  • Nanotechnology

About Shield Bio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Shield Bio builds a proprietary nanopore sequencing platform that produces results in under a minute at the point of care, replacing slower laboratory sequencing workflows that delay clinical decisions. The platform is designed for clinical settings and targets precision medicine, starting with infectious disease and sepsis, where rapid pathogen identification directly shapes treatment.

From the Y Combinator listing

How Shield Bio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Bringing 3rd generation, nanopore sequencing to healthcare to solve…

Shield Bio is a precision medicine company with a proprietary platform that enables reliable nanopore sequencing in under a minute, in a clinical setting. It is focused on bringing 3rd generation or "nanopore" sequencing into clinical use to deliver on the promise of precision medicine. Shield is initially using the technology to improve the treatment of infectious disease and address the unmet clinical need of sepsis, which kills 300,000 people a year in the US alone.

Facts

Industry
Healthcare / Healthcare -> Diagnostics
Location
San Jose, CA, USA
Team size
28
Status
Inactive
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works